B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates
about
Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.Polyreactivity and autoreactivity among HIV-1 antibodies.Natural IgM prevents autoimmunity by enforcing B cell central tolerance inductionHIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.The HIV-1 envelope protein gp120 is captured and displayed for B cell recognition by SIGN-R1(+) lymph node macrophages.HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells.Progress toward active or passive HIV-1 vaccination.Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1.Natural IgM and the Development of B Cell-Mediated Autoimmune DiseasesHuman Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.Generation of T-follicular helper cells in vitro: requirement for BCR cross-linking and cognate B- and T-cell interaction.Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.
P2860
Q30234773-89A2055A-AF1C-43C6-8336-D864B05874F4Q33594304-6818A8DD-44A5-4D46-A56B-43CEFF6B54DDQ34022578-4161F6A6-00BF-4C20-93F3-D3A2432DDCC8Q34992787-15B6DDC6-31BB-4FCB-A69B-4C5808346F69Q35072498-7E3977DE-E7A3-4BFB-B0D7-F74B446422F4Q35172770-91295F79-868C-48A0-A938-B4BD4DF82D17Q36071444-14CA8546-B6CD-4D06-9D4C-B11E9299573DQ36345558-F2F257F4-BAA3-442C-8B4C-11E645C190A4Q36957800-147BE838-B4E2-44B1-9548-35C7460B5F0FQ37549777-BCB165CC-B88C-45D7-BC8C-AF5772F1A6A4Q38219407-1BF96BD5-ED7F-4EE4-BD30-9B7B100BBF3DQ39026927-D221FB2C-DA6E-4191-80E0-D49A7CA2FCE7Q39108735-C74061E1-8481-4D16-BA1F-16474B5A825FQ39108760-4C1FF1A3-1508-4FE2-BFDF-AB81E7745C26Q40053462-1DF74A9B-BFFB-474D-B0D3-1080A374CA0CQ40679052-32EB14D8-5525-430C-A8F1-93C247B3D769Q47118310-4640AE35-4D33-455D-8BDD-B5927F4DA851
P2860
B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
B cells from knock-in mice exp ...... sive to HIV vaccine candidates
@en
B cells from knock-in mice exp ...... ive to HIV vaccine candidates.
@nl
type
label
B cells from knock-in mice exp ...... sive to HIV vaccine candidates
@en
B cells from knock-in mice exp ...... ive to HIV vaccine candidates.
@nl
prefLabel
B cells from knock-in mice exp ...... sive to HIV vaccine candidates
@en
B cells from knock-in mice exp ...... ive to HIV vaccine candidates.
@nl
P2093
P2860
P356
P1476
B cells from knock-in mice exp ...... sive to HIV vaccine candidates
@en
P2093
Anthony B Cooper
Colleen Doyle-Cooper
Dennis R Burton
Miyo Aoki-Ota
Richard T Wyatt
Takayuki Ota
William R Schief
P2860
P304
P356
10.4049/JIMMUNOL.1301283
P407
P577
2013-08-12T00:00:00Z